ABL1 and acute lymphoblastic leukemia: Ponatinib is a TKI targeting the T315I point mutation of BCR-ABL that is currently approved for chronic myeloid leukemia (CML) and Ph+ acute lymphoblastic leukemia (ALL) [23].